

Federal Research Regulations and Reporting Requirements: A New Framework for Research Universities in the 21st Century

Committee

Larry R. Faulkner

Chair

Larry R. Faulkner is President Emeritus of The University of Texas at Austin and is a retired president of Houston Endowment, a private philanthropy established by Jesse H. and Mary Gibbs Jones. Dr. Faulkner was born in Shreveport, Louisiana, in 1944. He earned a B.S. degree from Southern Methodist University in 1966 and a Ph.D. in chemistry from The University of Texas at Austin in 1969. Dr. Faulkner served on the chemistry faculties of Harvard University (1969-1973), the University of Illinois (1973-1983, 1984-1998), and the University of Texas (1983-1984, 1998-2006). At Illinois he was Head of the Department of Chemistry, Dean of the College of Liberal Arts and Sciences, and Provost and Vice Chancellor for Academic Affairs. In 1998, he returned to the University of Texas at Austin as the 27th president, and served into 2006. Faulkner became President of Houston Endowment Inc. immediately thereafter and ultimately retired in 2012.

Dr. Faulkner has published more than 120 scientific papers and directed 40 doctoral theses. He also is co-author (with Allen J. Bard) of the prominent text, *Electrochemical Methods: Fundamentals and Applications*, and is co-inventor (with Peixin He and James Avery) of the cybernetic potentiostat, which had a lasting impact on the design of commercial analytical instruments. He has been recognized with the Electrochemical Society's Edward Goodrich Acheson Medal, the American Chemical Society Award in Analytical Chemistry, the U.S. Department of Energy Award for Outstanding Scientific Achievement in Materials Chemistry, and the Charles N. Reilly Award of the Society for Electroanalytical Chemistry. In 2003, he was elected to the American Academy of Arts and Sciences.

As President of The University of Texas at Austin, he oversaw a capital campaign that raised over \$1.6 billion. He also appointed and supported the work of the Commission of 125, a citizens' group that provided guidance on the future of the University and its relationship to the public. Other significant achievements included the development of the Blanton Museum of Art, the acquisition of the Suida-Manning Collection of European Art and the Woodward-Bernstein Watergate Archive, and the creation of innovative scholarship programs that helped to restore UT's minority student enrollment. As President of Houston Endowment, he oversaw grantmaking of more than \$400 million to charities in Greater Houston focusing on arts and culture, education, the environment, health, and human services. From 2006 into 2008, he chaired the National Mathematics Advisory Panel by designation of the President and the Secretary of Education. From 2011 into 2013, he chaired the American Chemical Society's Presidential Commission on Advancing Graduate Education in the Chemical Sciences. Currently, he is vice-chair of the Texas Higher Education Coordinating Board's Higher Education Strategic Planning Committee.

He now serves on the boards of Exxon Mobil Corporation, Southern Methodist University, Discovery Green Conservancy, Houston Grand Opera, Reasoning Mind, the Philosophical Society of Texas, and Al Akhawayn University in Ifrane. He was previously on the boards of Temple-Inland, Sandia National Laboratories, and the Lyndon Baines Johnson Foundation, and he chaired the Board of Trustees of Internet2 for a three-year period ending in 2007.

Harriet Rabb

Vice Chair

Harriet Rabb, JD, is Vice President and General Counsel to the Rockefeller University. Ms. Rabb was also at Columbia Law School as a clinical professor, head of the clinical program and a member of the faculty during the course of her affiliation of more than two decades there. In 1991, she was named the first George M. Jaffin Professor of Law and Social Responsibility and, in 1992, added the title of vice dean of the law faculty. In 1998, she was the recipient of the Law School's Lawrence A. Wien Prize for Social Responsibility.

In 1993, Ms. Rabb was confirmed by the United States Senate to serve as general counsel for the U.S. Department of Health and Human Services under Secretary Donna Shalala. As chief legal officer of the Department, Ms. Rabb was responsible for legal matters involving, among other agencies, the National Institutes of Health, the Centers for Disease Control, the Food and Drug Administration, the Health Care Financing Administration and the Administration for Children and Families. Ms. Rabb led the Department's legal efforts on health policy issues, including human stem cell research, pandemic influenza, tobacco, assisted reproductive technology, tissue and organ allocation, fetal tissue and human embryo research, informed consent and various aspects of vaccines. In 2001, Ms. Rabb was named to her current position as vice president and general counsel to The Rockefeller University.

Ilesanmi Adesida

Member

Ilesanmi Adesida (NAE) is Vice Chancellor for Academic Affairs and Provost at the University of Illinois at Urbana-Champaign. He is the institution's chief academic officer. He oversees the campus' academic programs, policies and priorities, which have been designed to ensure the quality of the educational experience for students and to sustain an environment that encourages and supports academic excellence. As the chief academic officer, Provost Adesida works closely with the Chancellor, the other vice chancellors, the deans of academic colleges and other units, academic staff, the Faculty Senate, and various committees in setting overall academic priorities for the campus. In June 2005, Ilesanmi Adesida became the 13th dean since the inception of the College of Engineering in 1870. He originally joined the Illinois faculty in 1987, and he is currently the Donald Biggar Willett Professor of Engineering, Professor of Electrical and Computer Engineering, and Professor of Materials Science and Engineering. He has previously served as the Director of the Micro and Nanotechnology Laboratory and the Associate Director for Education of the NSF Engineering Research Center for Compound Semiconductor Microelectronics. Provost Adesida's research interests include nanofabrication processes and ultra-high-speed optoelectronics. He has extensive experience in development of novel processes for wide bandgap materials such as silicon carbide and gallium nitride. He has also worked on ultra-high-speed photodetectors and photoreceivers in various materials systems. Provost Adesida has chaired many international conferences, including serving as the Program and General Chair of the Electronic Materials Conference, 2000-2003. He is a Fellow of the Institute of Electrical and Electronic Engineers (IEEE), American Association for the Advancement of Science (AAAS), American Vacuum Society (AVS) and Optical Society of America. He is past-president of IEEE Electron Devices Society, and is a member of the National Academy of Engineering. He received his BS, MS, and PhD degrees in electrical engineering from the University of California, Berkeley. From 1979-84, he worked in various capacities at what is now known as the Cornell Nanofabrication Facility and the School of Electrical Engineering, Cornell University, Ithaca, NY. He was the head of the Electrical Engineering Department at Tafawa Balewa University, Bauchi, Nigeria, from 1985-87.

Ann M. Arvin

Member

Ann M. Arvin (IOM) is Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology & Immunology, Stanford University School of Medicine and Vice Provost and Dean of Research Stanford University. She was appointed Associate Dean of Research at Stanford University in 2001. Dr. Arvin's basic research program focuses on varicella-zoster virus, examining viral gene functions, molecular mechanisms of pathogenesis, and antiviral immunity, with NIAID support since 1981. Dr. Arvin's NIH-funded clinical research programs concern herpes viral infections in pregnancy and the newborn, developmental factors that shape the host response of infants and young children to viral pathogens, and the induction of cell-mediated immunity by vaccines against herpes viruses, measles and influenza. She is principal investigator of the NIAID Center for Human Immunology and Biodefense at Stanford. Dr. Arvin has served on numerous NIH panels, the FDA Vaccines and Related Biologics Advisory Committee, March of Dimes and HHMI committees, and the Council of the American Society for Virology. She was a member of the IOM Committee on the Assessment of Future Scientific Needs for Variola Virus, 1999, and the NIAID Expert Panel on Immunity and Biodefense Research, 2002, and now serves on the National Vaccine Advisory Committee, DHHS, and chairs the WHO Steering Committee on Measles Vaccine Research. She is an associate editor, Journal of Infectious Diseases and is on the editorial board of the Journal of Virology and other journals. Dr. Arvin has received the E. Mead Johnson Award of Society for Pediatric Research and the John Enders Award of Infectious Diseases Society of America, and is an elected member of the American Pediatric Society and the Association of American Physicians. She was elected to the Institute of Medicine of the National Academies in 2003. Dr. Arvin earned her undergraduate degree from Brown University, an M.A., Philosophy, from Brandeis University, and her M.D. degree from the University of Pennsylvania.

Barbara E. Bierer

Member

Barbara Bierer is the faculty co-chair of the Multi-Regional Clinical Trials Center at Harvard University (Harvard MRCT), a Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston and a hematologist/oncologist. She is the Director of the Regulatory Foundations, Ethics and the Law Program of the Harvard clinical and translational sciences center. Previously she served as senior vice president, research at the Brigham and Women's Hospital for 11 years, and was the institutional official for human subjects and animal research, for biosafety and for research integrity. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. In addition, she was the Founding Director of the Center for Faculty Development and Diversity at the BWH.

Dr. Bierer, a graduate of Harvard Medical School, completed her internal medicine residency at the Massachusetts General Hospital and her hematology and medical oncology training at the Brigham and Women's Hospital and the Dana-Farber Cancer Institute. Dr. Bierer maintained a research laboratory in the Department of Pediatric Oncology at Dana-Farber Cancer Institute and was appointed Director of Pediatric Stem Cell Transplantation at Dana-Farber Cancer Institute and Children's Hospital in 1993. In 1997, she was named Chief of the Laboratory of Lymphocyte Biology at the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, MD. She served on the Scholars Committee of the Howard Hughes Medical Institute and on the Biomedical Research Training Program for Underrepresented Minorities at NHLBI, where she received the Director's Award in 1999. She returned to the Dana-Farber Cancer Institute in July 2002 as Vice President of Patient Safety and Director of the Center for Patient Safety. In 2003, Dr. Bierer moved to the Brigham and Women's Hospital. In addition, in 2006, Dr. Bierer established the Center for Faculty Development and Diversity at the Brigham and Women's Hospital and now serves as its first director.

Jonathan D. Breul

Member

Jonathan D. Breul is Adjunct Professor, McCourt School of Public Policy, Georgetown University. He recently retired as the Executive Director of the IBM Center for The Business of Government. Previously, he was Senior Advisor to the Deputy Director for Management in the Office of Management and Budget, Mr. Breul served as OMB's senior career executive with primary responsibility for government-wide general management policies. He helped develop the President's Management Agenda, was instrumental in establishing the President's Management Council, and led the development and government-wide implementation of the Government Performance and Results Act. In addition to his OMB activities, he helped Senator John Glenn (D-Ohio) launch the Chief Financial Officers (CFO) Act. He also served for eight years as the U.S. delegate and elected vice chair of the Paris-based Organization for Economic Cooperation and Development's (OECD) Public Management Committee. Mr. Breul is an elected Fellow of the National Academy Public Administration (NAPA) and leads the Government Performance Coalition. He holds a Masters of Public Administration from Northeastern University, and a Bachelor of Arts from Colby College.

Claude R. Canizares

Member

Professor Canizares is Bruno Rossi Professor of Physics at MIT. He has responsibility for MIT's major international partnerships and oversees the MIT Lincoln Laboratory.

Claude Canizares is the Associate Director of the Chandra X-ray Observatory Center and a principal investigator on NASA's Chandra X-ray Observatory, having led the development of the Chandra High Resolution Transmission Grating Spectrometer. Canizares's main research interests are high resolution x-ray spectroscopy and plasma diagnostics of supernova remnants and clusters of galaxies, X-ray studies of dark matter, X-ray properties of quasars and active galactic nuclei, and observational cosmology. He is author or co-author of more than 230 scientific papers.

Claude Canizares earned his BA, MA and PhD in physics from Harvard University. He came to MIT as a postdoctoral fellow in the Physics Department in 1971 and joined the faculty in 1974. Canizares has received several awards, including decoration for Meritorious Civilian Service to the United States Air Force, two NASA Public Service Medals, and the Goddard Medal of the American Astronautical Society.

Arturo Casadevall

Member

Arturo Casadevall (IOM), MD, PhD is Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins University School of Public Health. Formerly, he was Leo and Julia Forchheimer Professor of Microbiology and Immunology; Chair, Department of Microbiology and Immunology; and Professor, Department of Medicine at the Albert Einstein College of Medicine. He received his BA from Queens College, CUNY, and MS, MD and PhD degrees from New York University. His laboratory is interested in the fundamental questions of how microbes cause disease and how the host protects itself against microbes. The laboratory has a multidisciplinary research program spanning several areas of basic immunology and microbiology to address these general questions, which has resulted over 430 publications. His laboratory studies are focused on two microbes: the fungus *Cryptococcus neoformans*, a ubiquitous environmental microbe that is a frequent cause of disease in immunocompromised individuals and *Bacillus anthracis*, which a major agent of biological warfare. He is a fellow of the American Academy of Microbiology and was elected to the American Society for Clinical Investigation, to the American Association of Physicians and as a fellow of the AAAS. Dr. Casadevall has served on numerous advisory committees to the NIH including study sections, strategic planning for the NIAID and the blue ribbon panel on response to bioterrorism. He currently co-chairs the Board of Scientific Counselors for the NIAID and is a member of the National Science Advisory Board for Biosecurity (NSABB). He an editor for *Infection and Immunity*, serves on the editorial boards of several journals, and has been the recipient of numerous awards, most recently the Solomon A. Berson Medical Alumni Achievement Award in Basic Science-NYU School of Medicine 2005 and the IDSA Kass Lecturer in 2008.

Jonathan R. Cole

Member

Jonathan R. Cole is the John Mitchell Mason Professor of the University. For fourteen years, from 1989 to 2003, he was Provost and Dean of Faculties of Columbia University—the second longest tenure as Provost in the University's 258-year history. He has spent his academic career at Columbia. From 1987 to 1989 he was Vice President of Arts and Sciences. His scholarly work focused principally on the development of the sociology of science as a research specialty. He lectures throughout the world on topics related to higher education.

Cole was a Fellow at the Center for Advanced Study in the Behavioral Sciences from 1975-76. He was awarded a John Simon Guggenheim Foundation Fellowship (1975-76). He spent the 1986-87 academic year as a Visiting Scholar at the Russell Sage Foundation. In 1992, he was elected a Fellow of the American Academy of Arts and Sciences. He is an elected Member of the American Philosophical Society; Member, Council on Foreign Relations; and Elected Fellow, American Association for the Advancement of Science. He received his B.A. in American History from Columbia College in 1964 and his Ph.D. in Sociology from Columbia in 1969. From 1968 until today, he has taught at Columbia. He was the Adolphe Quetelet Professor of Social Science, 1989 to 2001; Professor of Sociology, Columbia University from 1976 to present. He was Adjunct Professor at the Rockefeller University from 1983-1985. He has held the following administrative posts at Columbia: Director, Center for the Social Sciences, 1979-1987; Vice President of Arts and Sciences, Columbia University, 1987-1989; Provost and Dean of Faculties, Columbia University, 1989-2003.

Lee M. Ellis

Member

Lee M. Ellis, MD, is Professor of Surgical Oncology, and Molecular and Cellular Oncology and the William C. Liedtke, Jr. Chair in Cancer Research, at the University of Texas MD Anderson Cancer Center, and SWOG Vice Chair, Translational Medicine. Dr. Ellis graduated from the University of Virginia School of Medicine in 1983, and completed his residency in surgery at the University of Florida in 1990. Dr. Ellis went on to complete a surgical oncology fellowship at the M. D. Anderson Cancer Center (MDACC), where he has been on the faculty since 1993. Dr. Ellis has a clinical practice in Surgical Oncology, focused on patients with colorectal cancer and liver metastases. Academically, Dr. Ellis has established a reputation for expertise in the area of angiogenesis and growth factor receptors in gastrointestinal malignancies and is funded by several grants for research in this area. He has served on numerous NIH study sections and is a consultant to the National Cancer Institute, where he currently serves on the National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC), and is Vice Chair of the NCI Colon Task Force. In 2000, Dr. Ellis was awarded the Faculty Scholar Award from the MDACC, and he was also the inaugural recipient of a grant from the George and Barbara Bush Endowment for Innovative Cancer Research. In 2007, he was awarded the William C. Liedtke, Jr., Chair in Cancer Research. Dr. Ellis serves on 8 editorial boards, including serving as a Deputy Editor for JAMA Oncology. Dr. Ellis has also authored over 230 peer-reviewed publications, 110 invited reviews and editorials, four books, and 30 book chapters. Dr. Ellis served as Interim Chair, Department of Cancer Biology from 2008-2012 and he also served as Director of the Metastasis Research Center from 2010-2012 at the MDACC. Dr. Ellis served as Co-Director for the ASCO/AACR Workshop on Methods in Clinical Cancer Research from 2010-2012, and now serves as Co-Director of the FLIMS Workshop on Methods in Clinical Cancer Research. In May 2013, he assumed the position of Vice Chair for Translational Medicine of SWOG and serves on the Executive Committee for this organization. He is also on the Board of the Hope Foundation, the philanthropic arm of SWOG. Dr. Ellis is a member of the Nominating Committee of ASCO, a position he will hold until 2016. He chaired the ASCO Cancer Research Committee from 2012-2013.

Dr. Ellis's interest in data reproducibility was highlighted by a comment in Nature in 2012, followed by a survey on data reproducibility from investigators at the MD Anderson Cancer Center. He participated in a replication workshop held in at NCI/NIH in September 2012 and has lectured on this topic at numerous international meetings.

Geoffrey E. Grant

Member

Geoffrey E. Grant, President, Research Advocates

Mr. Grant has extensive management experience in public and academic institutions and has been recognized as an advocate for national research programs and the scientific community while promoting responsible stewardship of public funds. Geoff worked 25 at NIH, serving as Director of the Office of Policy for Extramural Research Administration before he went to Stanford University as Associate Vice President for Research Administration. He returned to Washington on a dual assignment at the National Science Foundation and the White House Office of Science and Technology Policy, where he worked with all Federal research agencies to streamline and facilitate multidisciplinary and interdisciplinary research. Geoff was later Vice President for Research Administration, Partners HealthCare one of the nation's leading biomedical research organizations with approximately \$1B of research support. He has received many honors and awards for research administration including appointment to the Federal Senior Executive Service, the Society of Research Administrators Distinguished Contribution to Research Administration award and the Association of Independent Research Institutes (AIRI) Public Service Award. He now consults universities on matters of research policy, regulation and compliance, and a nonprofit association on matters of regulatory infrastructure.

Joseph R. Haywood

Member

Joseph R. Haywood, PhD, is Professor of Pharmacology and Toxicology and Assistant Vice President for Regulatory Affairs at Michigan State University (MSU). He is President of Federation of American Societies for Experimental Biology (FASEB). In 2012, he served as FASEB Vice President for Science Policy and has also served as Chair of FASEB's Animals in Research & Education Subcommittee and Public Affairs Committee. Dr. Haywood is an active member of two FASEB societies. He is a member of the American Physiological Society and has served on its Council, and he is a member of the American Society for Pharmacology and Experimental Therapeutics. He has also been active in the leadership of the American Heart Association Council for High Blood Pressure Research. Dr. Haywood has served on the Council on Accreditation for the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and the Board of Governors of the International Council for Laboratory Animal Science (ICLAS). He co-chaired the committee that revised the CIOMS-ICLAS International Guiding Principles for the use of Animals in Research.

Dr. Haywood's research interests are in the area of neurohumoral control of arterial pressure, especially in experimental models of hypertension. He has focused on the action of circulating hormones and diet on neurotransmitter control of the paraventricular nucleus of the hypothalamus in regulating the sympathetic nervous system. Dr. Haywood received his PhD at the University of Florida and did post-doctoral work at the Cardiovascular Center at the University of Iowa. He rose through the ranks at the University of Texas Health Science Center at San Antonio before joining the Department of Pharmacology and Toxicology at MSU as Professor and Chair in 2002. In 2008 he became Assistant Vice President for Regulatory Affairs and remained as Department Chair until 2011. Dr. Haywood has served on editorial boards for the American Journal of Physiology, Hypertension, Physiological Genomics, and Clinical and Experimental Physiology and Pharmacology. Dr. Haywood has also served on a number of review panels for the National Institutes of Health.

Steven Joffe

Member

Steven Joffe is a pediatric oncologist and bioethicist who is currently the Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He is also the Director of the Penn Fellowship in Advanced Biomedical Ethics.

Dr. Joffe's research addresses the many ethical challenges that arise in the conduct of clinical and translational investigation. He has led NIH and foundation grants to study the roles and responsibilities of principal investigators in multicenter randomized trials, accountability in the clinical research enterprise, children's capacity to engage in research decisions, return of individual genetic results to participants in epidemiologic cohort studies, and the integration of whole-exome sequencing technologies into the clinical care of cancer patients. He has coauthored over 75 articles addressing these topics. He currently chairs the Children's Oncology Group Bioethics Committee, and serves as a member of the FDA's Pediatrics Ethics Subcommittee. Dr. Joffe attended Harvard College, received his medical degree from the University of California at San Francisco, and received his public health degree from UC Berkeley. He trained in pediatrics at UCSF and undertook fellowship training in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Boston Children's Hospital.

David Korn

Member

David Korn (IOM), BA, MD, Harvard University, is Professor of Pathology, Massachusetts General Hospital and Harvard Medical School. From November 15, 2008 to June 30, 2011, he was the inaugural Vice-Provost for Research at Harvard University. Prior to joining Harvard, Dr. Korn had served as the Chief Scientific Officer of the Association of American Medical Colleges (AAMC) in Washington, D.C. since January 15, 2007, and before that as the Senior Vice President for Biomedical and Health Sciences Research at the Association since September 1, 1997.

Dr. Korn served as Carl and Elizabeth Naumann Professor and Dean of the Stanford University School of Medicine from October 1984 to April 1995, and as Vice President of Stanford University from January 1986 to April 1995. Previously, he had served as Professor and Chairman of the Department of Pathology at Stanford, and Chief of the Pathology Service at the Stanford University Hospital, since June 1968. Dr. Korn has been Chairman of the Stanford University Committee on Research; President of the American Association of Pathologists (now the American Society for Investigative Pathology), from which he received the Gold-Headed Cane Award for lifetime achievement in 2004; President of the Association of Pathology Chairmen, from which he received the Distinguished Service Award in 1999; a member of the Board of Directors and of the Executive Committee of the Federation of American Societies for Experimental Biology; and a member of the Board of Directors of the Association of Academic Health Centers.

Dr. Korn served on the Board of Directors of the Stanford University Hospital from October 1982 to April 1995, the Children's Hospital at Stanford from October 1984 to its closure, and the Lucile Salter Packard Children's Hospital at Stanford from October 1984 to April 1995. He was a member of the Board of Directors of the California Society of Pathologists from 1983-86. Dr. Korn has been a member of the editorial boards of the American Journal of Pathology, The Journal of Biological Chemistry, and Human Pathology, and for many years was an Associate Editor of the latter. He has sat on many Society Councils and Boards. His more than 250 publications range from bacteriophage biochemistry and genetics to the biochemistry and molecular biology of DNA replication in human cells, and more recently, concern issues of academic values and integrity, research integrity, health and science policy, and financial conflicts of interest in academic medicine.

Charles F. Louis

Member

Charles Louis is Professor of Neuroscience and Cell Biology at the University of California, Riverside and former Vice Chancellor for Research. Dr. Louis served as Vice President for Research at Georgia State University from 2000-2004, having previously served on the faculty at the University of Minnesota for over 20 years where he held a number of administrative positions that included Head of the Department of Biochemistry, Molecular Biology and Biophysics from 1998-2000 and Assistant Vice President for Research and Associate Dean of the Graduate School from 1994-1998. He previously held faculty appointments at the University of Connecticut Health Center, and Leeds University in England.

Dr. Louis' biomedical research on the role of calcium as an intracellular signaling molecule, which has been funded by the National Institutes of Health for over 25 years, uses a range of different approaches including cell physiology, molecular biology, biochemistry, cell biology, and biophysics. His current research program focuses on the role of gap junctions in the development of cataracts in the lens of the eye because an elevation in cytosolic calcium concentration which closes these cell-to-cell channels is one of the critical early steps in the development of lens cataract formation. Dr. Louis is Chair of the Executive Committee of the Council of Research Policy and Graduate Education (CRPGE) of the Association of Public and Land-Grant Universities (APLU) serving on the Board of Directors of APLU, and a member of the Board of Directors of the Council on Government Relations (COGR); he has served on many peer-review grant committees as well as the boards of biotech industry associations in both Minnesota and Georgia. Dr. Louis received his Bachelor of Arts degree in Chemistry from Trinity College, Dublin, Ireland, his Doctorate of Philosophy in Biochemistry from Oxford University, and post-doctoral training at Stanford University.

David W. Robinson

Member

David W. Robinson, PhD, is currently Professor and Executive Vice Provost at Oregon Health and Science University in Portland, Oregon. He obtained a B.Sc. in Physiology at University College London and a Ph.D. at Cambridge University. In 1992, he moved to the United States to do post-doctoral training at the University of California at Davis, where he subsequently became a research track faculty member before moving to Oregon Health & Sciences University (OHSU) in 1997.

Robinson holds a faculty appointment as Professor in the Department of Physiology and Pharmacology with joint appointments in the Department of Ophthalmology and the Center for Research on Occupational and Environmental Toxicology. At OHSU, Dr. Robinson's administrative work began as the Senior Technology Advisor for Research and Education in 2000. Subsequent to that, he served as Vice Provost for Academic Technology (2006), Director of Educational Communications (2006), Interim University Librarian (2008), Vice Provost for Academic Technology and Information Services (2008), Interim Provost for Education and Research (2009), and Interim Provost and Vice President for Academic Affairs (2010) before receiving his current appointment. Dr. Robinson has also been the OHSU faculty representative to the Federal Demonstration Partnership (<http://www.thefdp.org/>) 2002. The FDP is a 25 year old association that presently comprises 10 Federal Agencies and 120 academic institutions with more than \$15 billion in federal research grants. In 2008 David was elected for a 3-year term to the position of Vice Chair and works closely with senior staff members from the FDP's Federal Agency partners (NIH, NSF, ONR, UDASA, AFOSR, ARO, AMRMC, NASA, EPA and DHS), the Office of Science and Technology Policy, and the National Academies to improve the administrative processes involved with receiving funding from the Federal Government.

Thomas J. Rosol

Member

Thomas J. Rosol, DVM, PhD is Professor, Veterinary Biosciences and Special Assistant to the Vice President for Research, The Ohio State University. He served as the Senior Associate and Interim Senior Vice President for Research (2002-2005) and Dean of the College of Veterinary Medicine (2005-2008) at The Ohio State University. Rosol currently serves a Senior Advisor, Life Sciences for the university's Office of Technology Commercialization and Knowledge Transfer and Special Assistant to the Senior Vice President for Research.

Dr. Rosol maintains an active, NIH-funded research laboratory that uses molecular, in vitro, and in vivo techniques to investigate the pathogenesis of human and animal cancers. Specifically, the laboratory develops mouse models of cancer to study the pathogenesis of bone metastasis, cancer-associated hypercalcemia, and human HTLV-1-induced T-cell lymphoma. The Rosol laboratory has developed mouse models of human cancer that mimic metastases in humans and are used to investigate the pathogenesis and treatment of metastasis. New laboratory expertise has been developed for in vivo imaging of cancer in mouse models using bioluminescence, high resolution ultrasound, microCT, and near infrared imaging of molecular markers. The lab is also examining the ability of nanoparticles to enhance the ultrasound imaging of cancer molecular markers.

Stuart Shapiro

Member

Stuart Shapiro joined the Bloustein school faculty in 2003 after five years in the Office of Information and Regulatory Affairs (OIRA) at the Office of Management and Budget (OMB) in Washington. In OIRA he analyzed and coordinated executive branch review in the areas of labor, health and social policy. Prior to working at OIRA he received his Ph.D in Public Policy from Harvard University where he studied how political factors impacted changes to child care regulations in eight states. He has taught courses at Harvard, Georgetown, and the USDA Graduate School. His research interests include the regulatory process, the use of cost-benefit analysis, the Federal bureaucracy, and the civil service system. His recent publications include "Agency Oversight as 'Whac-a-Mole': The Challenge of Restricting Agency Use of Nonlegislative Rules" Harvard Journal of Law and Public Policy; The Politics of Regulatory Reform, Routledge, "Does Haste Make Waste? How Long Does It Take to do a Good Benefit-Cost Analysis" Administration and Society; "The Triumph of Regulatory Politics: Benefit-Cost Analysis and Political Salience" Regulation and Governance; and "OIRA Inside and Out" Administrative Law Review.

Anne-Marie C. Mazza

Staff Officer